Treatment with 32-134D led to (a) decreased expression of CA9, CXCL1, EPO, LDHA, PGF, SCF/KITLG, and SLC2A1/GLUT1 mRNA, which are all associated with HCC patient mortality; and (b) increased expression of CCL12/CCL2, CXCL2, CXCL9, CXCL10, and HC/C5 mRNA, which are all associated with HCC patient survival (Supplemental Table 2). Here, CXCL2 is linked to hepatocellular carcinoma.